In a recently reported phase 1b study, the novel peripherally acting Cannabinoid Receptor-1 (CB1R) inverse agonist, INV-202 (monlunabant), was evaluated in a placebo-controlled trial over 28 days in participants with obesity and features of metabolic syndrome and glucose intolerance [119]. Here, CNR1 is linked to obesity due to melanocortin 4 receptor deficiency.